Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment

Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasagna, Angioletta, Cassaniti, Irene, Lilleri, Daniele, Quaccini, Mattia, Ferrari, Alessandra, Sacchi, Paolo, Bruno, Raffaele, Baldanti, Fausto, Pedrazzoli, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643502/
https://www.ncbi.nlm.nih.gov/pubmed/36388947
http://dx.doi.org/10.3389/fmed.2022.1036473
_version_ 1784826542147239936
author Lasagna, Angioletta
Cassaniti, Irene
Lilleri, Daniele
Quaccini, Mattia
Ferrari, Alessandra
Sacchi, Paolo
Bruno, Raffaele
Baldanti, Fausto
Pedrazzoli, Paolo
author_facet Lasagna, Angioletta
Cassaniti, Irene
Lilleri, Daniele
Quaccini, Mattia
Ferrari, Alessandra
Sacchi, Paolo
Bruno, Raffaele
Baldanti, Fausto
Pedrazzoli, Paolo
author_sort Lasagna, Angioletta
collection PubMed
description Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients with solid tumors on active treatment to examine the effectiveness of these drugs in preventing the progression to severe COVID-19. Sixty-nine patients with solid tumors (43 women, 26 men; median age 61, range 26–80) reported a laboratory-confirmed diagnosis of SARS-CoV-2 infection. Forty-nine patients received early therapy. Only one patient (14.5%) required hospitalization for COVID-19. As for safety, two patients (5.9%) reported nausea during nirmatrelvir/ritonavir. The majority of treated patients showed a reduced time to negative sample (73 vs. 18%, p = 0.0011) and shorter symptoms’ duration (94 vs. 27%; p < 0.0001) compared to the patients not treated with the early COVID-19 therapies. Our data suggest that early therapies may reduce the morbidity of COVID-19 in patients with solid tumors.
format Online
Article
Text
id pubmed-9643502
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96435022022-11-15 Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment Lasagna, Angioletta Cassaniti, Irene Lilleri, Daniele Quaccini, Mattia Ferrari, Alessandra Sacchi, Paolo Bruno, Raffaele Baldanti, Fausto Pedrazzoli, Paolo Front Med (Lausanne) Medicine Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients with solid tumors on active treatment to examine the effectiveness of these drugs in preventing the progression to severe COVID-19. Sixty-nine patients with solid tumors (43 women, 26 men; median age 61, range 26–80) reported a laboratory-confirmed diagnosis of SARS-CoV-2 infection. Forty-nine patients received early therapy. Only one patient (14.5%) required hospitalization for COVID-19. As for safety, two patients (5.9%) reported nausea during nirmatrelvir/ritonavir. The majority of treated patients showed a reduced time to negative sample (73 vs. 18%, p = 0.0011) and shorter symptoms’ duration (94 vs. 27%; p < 0.0001) compared to the patients not treated with the early COVID-19 therapies. Our data suggest that early therapies may reduce the morbidity of COVID-19 in patients with solid tumors. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643502/ /pubmed/36388947 http://dx.doi.org/10.3389/fmed.2022.1036473 Text en Copyright © 2022 Lasagna, Cassaniti, Lilleri, Quaccini, Ferrari, Sacchi, Bruno, Baldanti and Pedrazzoli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Lasagna, Angioletta
Cassaniti, Irene
Lilleri, Daniele
Quaccini, Mattia
Ferrari, Alessandra
Sacchi, Paolo
Bruno, Raffaele
Baldanti, Fausto
Pedrazzoli, Paolo
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
title Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
title_full Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
title_fullStr Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
title_full_unstemmed Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
title_short Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
title_sort effectiveness of the available early therapies in reducing severe covid-19 in non-hospitalized patients with solid tumors on active treatment
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643502/
https://www.ncbi.nlm.nih.gov/pubmed/36388947
http://dx.doi.org/10.3389/fmed.2022.1036473
work_keys_str_mv AT lasagnaangioletta effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT cassanitiirene effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT lilleridaniele effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT quaccinimattia effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT ferrarialessandra effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT sacchipaolo effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT brunoraffaele effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT baldantifausto effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment
AT pedrazzolipaolo effectivenessoftheavailableearlytherapiesinreducingseverecovid19innonhospitalizedpatientswithsolidtumorsonactivetreatment